Trial Profile
Randomized control study to evaluate efficacy and safety of tenofovir alafenamide fumarate for chronically HBV-infected patients treated with entecavir
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- 26 Jan 2021 Status changed to active, no longer recruiting.
- 16 Apr 2018 New trial record